Astrazeneca (AZN) Capital Expenditures (2009 - 2026)

Astrazeneca (AZN) has reported Capital Expenditures for 17 consecutive years, with -$547.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures fell 27.51% year-over-year to -$547.0 million; the TTM figure through Mar 2026 stood at $2.7 billion (up 40.79% YoY), while the FY2025 annual figure was $2.8 billion, up 46.05% from the prior year.
• Capital Expenditures came in at -$547.0 million for Q1 2026 at Astrazeneca, down from $4.6 billion in the prior quarter.
• The five-year high for Capital Expenditures was $4.6 billion in Q4 2025, with the low at -$686.0 million in Q3 2025.
• Average Capital Expenditures over 5 years is $246.0 million, with a median of -$382.0 million recorded in 2024.
• The largest YoY upside for Capital Expenditures was 45.99% in 2025 against a maximum downside of 72.51% in 2025.
• Year by year, Capital Expenditures stood at -$253.0 million in 2022, then retreated by 6.72% to -$270.0 million in 2023, then surged by 1262.96% to $3.1 billion in 2024, then surged by 45.99% to $4.6 billion in 2025, then sank by 111.93% to -$547.0 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered -$547.0 million, $4.6 billion, and -$686.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.